At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
ranibizumab 0.3mgdrug
Likely dose
ranibizumab 0.3mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Foveal Involving Edema and Lipid Exudates
South Coast Retina Center; Carson, McBeath, Boswell, Inc.·interventional·Posted May 19, 2015·Updated Jul 8, 2021
In Brief
A Phase 2 clinical trial evaluating ranibizumab 0.3mg for Diabetic Macular Edema and Hard Lipid Exudates. Completed, enrolled 25 participants across 4 sites.
Detailed Summary
This is an open-label, Phase I/II study of intravitreally administered 0.3mg ranibizumab in subjects with diabetic macular edema and lipid exudates in the central subfield.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema, Hard Lipid Exudates
CountriesUnited States
CollaboratorsGenentech, Inc., Doheny Image Reading Center, The Retina Partners
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 2015
Enrollment StartAug 2015
Primary CompletionMay 2018
TodayJul 2026
First PostedMay 19, 2015
Enrollment StartAug 1, 2015
Primary CompletionMay 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 11.1 years ago
Interventions
ranibizumab 0.3mgdrug
intravitreally administered